Leitat, a part of the innovative project GUTBABI to improve intestinal health in early childhood

In an era where science and technology play a fundamental role in the well-being of future generations, the GUTBABI project marks a significant milestone in the research and development of functional foods aimed at strengthening gut health in the early years of life. This ambitious project has been conceived with the goal of developing a functional complementary food that contributes to establishing a healthy gut microbiota in infants, a key factor for their development and long-term health. Under the leadership of Fruselva, GUTBABI benefits from the collaboration of a multidisciplinary consortium that includes Leitat (Health & Biomedicine Department), IISPV-URV (Research Unit in Pediatrics, Nutrition, and Human Development – PEDINUR), ALGEMY, and i-GRAPE.

 A critical phase in child development

The transition period to complementary feeding represents a crucial moment in infant development. During this stage, the gut microbiota undergoes significant changes while the immune system strengthens. At the same time, babies are exposed to a higher risk of infections due to contact with broader social environments, such as daycare centers, increasing the need for specific immune support. Recognizing this vulnerability, the GUTBABI project aims to offer a solution based on a functional food that, thanks to the incorporation of bioactive compounds derived from microalgae and polyphenol-rich sources, promotes a robust microbial environment to support health and well-being in childhood.

Innovative and rigorous methodology

GUTBABI’s research approach is structured into five main activities:

1. Systematic review to identify bioactive compounds with beneficial properties.
2. Research on sustainable extraction technologies and comprehensive characterization of the innovative ingredients obtained.
3. In vitro and in vivo validation to ensure the safety and efficacy of the compounds.
4. Formulation of a functional complementary food, subjected to a rigorous sensory evaluation.
5. Design and execution of a clinical trial to assess the product’s impact on gut microbiota composition, its ability to strengthen the immune system, and its potential to reduce infection rates in infants.

A multidisciplinary consortium

GUTBABI has been structured through a consortium that combines the strengths of academic, technological, and industrial institutions. Fruselva, a recognized leader in infant food, leads the project, contributing its expertise in formulating and producing foods tailored to the needs of young children. Among its partners, Leitat brings its experience in technology and innovation in functional food for biomedical purposes, IISPV-URV leads clinical and microbiological research, ALGEMY specializes in microalgae-derived compounds, and i-GRAPE contributes its expertise in polyphenols and antioxidants.

Expected impact and key outcomes

GUTBABI aims to generate significant advances in several areas:

• Development of innovative biomarkers to assess pediatric gut health.
• Advances in sustainable technologies for extracting bioactive compounds.
• New insights into the role of gut microbiota in early development.
• Creation of a clinically validated functional complementary food ready for the market.

The project will also contribute to generating scientific evidence to document the benefits of functional products in child health, thereby strengthening consumer confidence and meeting the most demanding regulatory requirements.

Towards a healthier future

With an approach that combines cutting-edge science and practical application, GUTBABI has the potential to transform infant care. This project reinforces the commitment of Fruselva and its partners to developing solutions that positively impact public health, laying the foundations for a healthier and more resilient childhood.